REVELATION BIOSCIENCES, INC. (REVB): Nasdaq/NYSE listing notice — Revelation Biosciences receives Nasdaq delisting notice; trading to be suspended Dec 2, 2022

REVELATION BIOSCIENCES, INC.

Received second Nasdaq deficiency letter on Nov 23, 2022 for failing $2.5M stockholders' equity requirement.
As of Sept 30, 2022, stockholders' equity was $2,227,768, below the minimum.
Trading suspension scheduled for Dec 2, 2022 unless appeal is filed.
Company intends to request hearing before an independent panel to stay suspension.
No immediate effect on trading of units, common stock or warrants under REVBU, REVB, REVBW.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

REVELATION BIOSCIENCES, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

While the Company did complete a $5 million offering in July 2022, in the Form 10-Q for the quarter ended September 30,2022 the Company reported a stockholders’ equity of $2,227,768, less than the Stockholders’ Equity Requirement. As a result, on November 23, 2022, the Company received a further deficiency letter (the “Second Nasdaq Letter”). The Second Nasdaq

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

REVELATION BIOSCIENCES, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

Equity Requirement was based on the Company’s filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, reporting the stockholders’ deficit of $98,511. Pursuant to the First Nasdaq Letter, the Company submitted a plan to regain compliance and the Company which contemplated capital raises of $10 million, following which Nasdaq

View on SEC.gov

19 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

REVELATION BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001213900-22-075030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.